Results 151 to 160 of about 1,536,180 (350)

I-ACT for Children: helping close the gap in drug approval for adults and children. [PDF]

Pediatr Res, 2023
Coppes MJ, Jackson C, Connor EM.
europepmc   +1 more source

Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval [PDF]

, 2004
David L. Selwood
openalex   +1 more source

Targeting carbonic anhydrase IX/XII prevents the anti‐ferroptotic effect of stromal lactic acid in prostate carcinoma

Molecular Oncology, EarlyView.
In prostate carcinoma, lactic acid, secreted by highly glycolytic cancer‐associated fibroblasts, is imported into tumor cells through the MCT1 transporter and prevents RSL3 and erastin‐induced ferroptosis (A). Targeting of carbonic anhydrase IX/XII, the main extracellular pH regulators, in tumor and stromal cells reduces microenvironmental acidosis and
Elisa Pardella, Giuseppina Comito, Luigi Ippolito, Erica Pranzini, Marta Iozzo, Giulia Gangarossa, Francesca Virgilio, Silvia Bua, Alessio Nocentini, Giada Sandrini, Nicla Lorito, Marina Bacci, Gabriella Nesi, Pietro Spatafora, Sergio Serni, Claudiu T. Supuran, Andrea Morandi, Paola Chiarugi, Elisa Giannoni   +18 more
wiley   +1 more source

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway

Journal of Pharmaceutical Policy and Practice
Background Withdrawals of drug indications may reveal potential inadequacies in the regulatory approval processes of new drugs. Understanding potential weaknesses of the regulatory approval process is paramount given the increasing use of expedited ...
Mahnum Shahzad, Huseyin Naci, Katharine M. Esselen, Joseph A. Dottino, Anita K. Wagner   +4 more
doaj   +1 more source

Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis. [PDF]

Paediatr Drugs, 2022
Case SM, Nigrovic PA.
europepmc   +1 more source

Accelerated Approval Seen as Triumph and Roadblock for Cancer Drugs [PDF]

, 2004
Elizabeth J. Susman
openalex   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis

, 1999
Andrea Meyerhoff
openalex   +1 more source

'Fast-track' drug approvals hit speed bumps in Japan [PDF]

, 2004
Douglas Sipp
openalex   +1 more source

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

Molecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li, Zhijie Cao, Haiyan Xing, Zhenya Xue, Wenbing Liu, Jiayuan Chen, Yihan Mei, Runxia Gu, Hui Wei, Shaowei Qiu, Min Wang, Qing Rao, Jianxiang Wang   +12 more
wiley   +1 more source